Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function
• MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently
• Backed by blue chip international investors

Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics that enhance mitophagy to promote cell/organ health, today announces it has raised £25.2 million to progress the clinical development of its drug candidates. The financing was jointly led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital.

Read more…